CP 93129 Dihydrochloride | 879089-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: CP 93129 Dihydrochloride
• 英文别名: 3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one;dihydrochloride
• CAS: 879089-64-2
• 化学式: C12H15Cl2N3O
• 分子量: 288.17
• InChiKey: FLVJHUZZKVJQNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.08
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56.9
• 氢给体数：
  5
• 氢受体数：
  2

文献信息

• USE OF BUSPIRONE METABOLITES
  申请人：Contera Pharma APS

  公开号：EP3160464A1

  公开（公告）日：2017-05-03
• 6-HYDROXYBUSPIRONE FOR USE IN THE TREATMENT OF MOVEMENT DISORDERS
  申请人：Contera Pharma APS

  公开号：EP3160464B1

  公开（公告）日：2018-07-18
• COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS
  申请人：Hansen John Bondo

  公开号：US20140221385A1

  公开（公告）日：2014-08-07

  The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
• [EN] COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS<br/>[FR] COMBINAISONS D'AGONISTES DE RÉCEPTEUR DE SÉROTONINE POUR LE TRAITEMENT DE TROUBLES DU MOUVEMENT
  申请人：CONCIT PHARMA APS

  公开号：WO2012163365A1

  公开（公告）日：2012-12-06

  The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
• [EN] USE OF BUSPIRONE METABOLITES<br/>[FR] UTILISATION DE MÉTABOLITES DE LA BUSPIRONE
  申请人：CONTERA PHARMA APS

  公开号：WO2015197079A1

  公开（公告）日：2015-12-30

  The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.